In the second installment of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, provide insights on the multidisciplinary approach to treating patients with prostate cancer and discuss the roles of urologists and radiation oncologists.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.